Regional versus systemic delivery of recombinant vaccinia virus as suicide gene therapy for murine liver metastases

Annals of Surgery

Volumn 230, Issue 3, 1999, Pages 352-361

  Gnant, Michael F X ^a,b,d   Puhlmann, Markus ^a,c   Bartlett, David L ^a   Alexander Jr , H Richard ^a,e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF VIENNA   (Austria)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d Max Kade Foundation   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; LUCIFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CANCER CHEMOTHERAPY; COLON CARCINOMA; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; LIVER METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE; SUICIDE GENE; TISSUE DISTRIBUTION; TRANSGENE; TREATMENT OUTCOME;

ADENOCARCINOMA; ANIMALS; CYTOSINE DEAMINASE; ESCHERICHIA COLI; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER TECHNIQUES; LIVER NEOPLASMS; LUCIFERASES; MICE; NUCLEOSIDE DEAMINASES; SURVIVAL RATE; TRANSFECTION; VACCINIA VIRUS;

EID: 0033497865     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-199909000-00008     Document Type: Conference Paper

References (51)

1. Pisani P, Parkin DM, Ferlay J. Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 1993; 55:891-903.
2. Bengmark S, Hafstrom L. The natural history of primary and secondary malignant tumors of the liver. I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy. Cancer 1969; 23:198-202.
3. Zavadsky KE, Lee YT. Liver metastases from colorectal carcinoma: incidence, resectability, and survival results. Am Surg 1994; 60:929-933.
4. Bismuth H, Adam R, Navarro F, Castaing D, Engerran L, Abascal A. Re-resection for colorectal liver metastasis. Surg Oncol Clin North Am 1996; 5:353-364.
5. van der Vilt CL, Smid K, Aherne GW, Noordhuis P, Peters GJ. Biochemical mechanisms of interferon modulation of 5-fluorouracil activity in colon cancer cells. Eur J Cancer 1997; 33:471-478.
6. Tannock IA. Conventional cancer therapy: promise broken or promise delayed? Lancet 1998; 351:SII9-SII16
7. Zwacka RM, Dunlop MG. Gene therapy for colon cancer. Gene Ther 1998; 12:595-615.
8. Rowley S, Lindauer M, Gebert JF, et al. Cytosine deaminase gene as a potential tool for the genetic therapy of colorectal cancer. J Surg Oncol 1996; 61:42-48.
9. Huber BE, Richards CA, Austin EA. Virus-directed enzyme/prodrug therapy (VDEPT). Ann NY Acad Sci 1994; 716:104-114.
10. Gabel M, Kim HJ, Kolozsvary A, Khil M, Freytag S. Selective in vivo radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells transduced with the E. coli cytosine deaminase (CD) gene. Int J Radiat Oncol Biol Phys 1998; 41:883-887.
11. Huber BE, Austin EA, Good SS, Knick VC, Tibbels S, Richards CA. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res 1993; 1:4619-4626.
12. Singhal S, Kaiser LR. Cancer chemotherapy using suicide genes. Surg Oncol Clin North Am 1998; 7:505-536.
13. Peplinski GR, Tsung K, Norton JA. Vaccinia virus for human gene therapy. Surg Oncol Clin North Am 1998; 7:575-588.
14. Fenner F, Henderson DA, Aritz I, Jezek Z, Ladnyi ID. Smallpox and its eradication. Geneva: World Health Organization; 1988.
15. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA 1996; 93:11341-11348.
16. Peplinski GR, Tsung K, Whitman ED, Meko JB, Norton JA. Construction and expression in tumor cells of a recombinant vaccinia virus encoding human interleukin-1β. Ann Surg Oncol 1995; 2:151-159.
17. Peplinski GR, Tsung K, Meko JB, Norton JA. Prevention of murine breast cancer by vaccination with tumor cells modified by cytokine-producing recombinant vaccinia viruses. Ann Surg Oncol 1996; 31: 15-23.
18. Puhlmann M, Brown CK, Gnant M, et al. Vaccinia as a vector for tumor directed gene therapy: biodistribution of a thymidine kinase deleted mutant. Cancer Gene Ther 1999 (in press).
19. Gnant MFX, Puhlmann M, Alexander HR Jr, Bartlett DL. Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor specific gene expression and cures of established liver metastases. Cancer Res 1999 (in press).
20. Gnant M, Noll L, Irvine KR, et al. Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of unresectable liver metastases: pattern of gene expression, vector elimination and immune response. JNCI 1999 (in press).
21. Davison AJ, Moss B. Structure of vaccinia virus early promoters. J Mol Biol 1989; 210:749-769.
22. Davison AJ, Moss B. Structure of vaccinia virus late promoters. J Mol Biol 1989; 210:771-784.
23. Earl PL, Moss B. Current protocols in molecular biology. In: Ausubel FM, Kinston R, Kingston RE, et al., eds. Current protocols in molecular biology. New York: Greene/Wiley Interscience; 1991:16.15.1-16.18.10.
24. Corbett TH, Griswold DP, Roberts BJ. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res 1975; 35:2434-2439.
25. Lafreniere G, Rosenberg SA. A novel approach to the generation and identification of experimental hepatic metastases in a murine model. JNCI 1986; 76:309-322.
26. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53:457-481.
27. Mantel N. Evaluation of survival data and two new rank-order statistics arising in its consideration. Cancer Chem Rep 1966; 50:163-170.
28. Dachs GU, Dougherty GJ, Stratford IJ, Chaplin DJ. Targeting gene therapy to cancer: a review. Oncol Res 1997; 9:313-325.
29. Moolten FL. An alternative to the magic bullet paradigm for specific cancer therapy. Med Hypotheses 1987; 24:43-51.
30. Moolten FL, Wells JM, Heyman RA, Evans RM. Lymphoma regression induced by ganciclovir in mice bearing a herpes thymidine kinase transgene. Hum Gene Ther 1990; 1:125-134.
31. Huber BE, Richards CA, Krenitsky TA. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc Natl Acad Sci USA 1991; 15:8039-8043.
32. Ju DW, Cao X, Acres B. Intratumoral injection of GM-CSF gene encoded recombinant vaccinia virus elicits potent antitumor response in a murine melanoma model. Cancer Gene Ther 1997; 4:139-144.
33. Bass C, Cabrera G, Elgavish A, et al. Recombinant adenovirus-mediated gene transfer to genitourinary epithelium in vitro and in vivo. Cancer Gene Ther 1995; 2:97-104.
34. de Roos WK, Fallaux FJ, Marinelli AWKS, et al. Isolated-organ perfusion for local gene delivery: efficient adenovirus-mediated gene transfer into the liver. Gene Ther 1997; 4:55-62.
35. Lee SS, Einsenlohr LC, McCue PA, Mastrangelo MJ, Lattime EC. Intravesical gene therapy: in vivo gene transfer using recombinant vaccinia virus vectors. Cancer Res 1994; 54:3325-3328.
36. Topf N, Worgall S, Hackett NR, Crystal RG. Regional pro-drug gene therapy: intravenous administration of an adenoviral vector expressing the E coli cytosine deaminase gene and systemic administration of 5-fluorocytosine suppresses growth of hepatic metastasis of colon carcinoma. Gene Ther 1998; 5:507-513.
37. Chung CS, Hsiao JC, Chang YS, Chang W. A27L protein mediates vaccinia virus interaction with cell surface heparin sulfate. J Virol 1998; 72:1577-1585.
38. Brunner G, Reimbold K, Meissauer A, Schirrmacher V, Erkell LJ. Sulfated glycosaminoglycans enhance tumor cell invasion in vitro by stimulating plasminogen activation. Exp Cell Res 1998; 239:301-310.
39. Martin LA, Vile R, Lemoine NR, Sikora K, Pandha HS. Genetic prodrug activation therapy. Lancet 1997; 350:1793-1794.
40. Trinh QT, Austin EA, Murray DM, Knick VC, Huber BE. Enzyme/ prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res 1995; 55:4808-4812.
41. Richards CA, Austin EA, Huber BE. Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase for tumor-specific gene therapy. Hum Gene Ther 1995; 6:881-893.
42. Moss B. Replicating and host-restricted non-replicating vaccinia virus vectors for vaccine development. Dev Biol Stand 1994; 82:55-63.
43. Hirschowitz EA, Ohwada A, Pascal WR, Russi TJ, Crystal RG. In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Hum Gene Ther 1995; 6:1055-1063.
44. Mullen CA, Petropoulos D, Lowe RM. Treatment of microscopic pulmonary metastases with recombinant autologous tumor vaccine expressing interleukin 6 and Escherichia cali cytosine deaminase suicide genes. Cancer Res 1996; 56:1361-1366.
45. Zhang J, Russell SJ. Vectors for cancer gene therapy. Cancer Metastasis Rev 1996; 15:385-401.
46. Caruso M, Panis Y, Gagandeep S, Houssin D. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci USA 1993; 90:7024-7028.
47. Kim CJ, Cormier J, Roden M, et al. Use of recombinant poxviruses to stimulate anti-melanoma T cell reactivity. Ann Surg Oncol 1998; 5:64-76.
48. Dolin R. Human studies in the development of human immunodeficiency virus vaccines. J Infect Dis 1995; 172:1175-1183.
49. Paoletti E. Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci USA 1996; 93:11349-11353.
50. McAneny D, Ryan CA, Beazley RM, Kaufman HL. Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer. Ann Surg Oncol 1996; 3:495-500.
51. Cooney EL, Collier AC, Greenberg PD, et al. Safety of an immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 1991; 337:567-572.